publication date: Jul. 17, 2015

Georgetown Lombardi and John Theurer to Form Cancer Research Consortium 


GEORGETOWN LOMBARDI Comprehensive Cancer Center and John Theurer Cancer Center, part of Hackensack University Medical Center, developed a joint cancer research agenda as part of a multi-year plan to form a NCI-recognized cancer consortium.

Georgetown Lombardi is an NCI-designated comprehensive cancer center. Through the partnership, John Theurer Cancer Center is working to secure this NCI designation as well.

Among the planned joint research projects is blood stem cell transplantation and immunotherapy clinical research at Washington DC’s Blood and Marrow Stem Cell Transplant Program, established in 2013 by John Theurer and MedStar Georgetown University Hospital, Georgetown Lombardi’s clinical partner.

The research areas include expansion of clinical bone marrow transplant research; clinical study of haplo transplants, the use of half-matched stem cell donor cells; re-engineering the function and focus of key immune cells; and the investigation of immune checkpoint blocking antibodies.

Next generation genomic sequencing research will utilize the Clinical Outcomes Tracking & Analysis Platform, a large cancer patient treatment and outcomes database developed by John Theurer Cancer Center to sort patients and reduce variance.

The two organizations will also explore population science research and expand existing programs focused on the characteristics of patients in the greater Washington and the northern New Jersey areas. The John Theurer Cancer Center will establish a Cancer Prevention and Control office and Georgetown Lombardi will expand its population science research using the COTA database platform.


CITY OF … Continue reading 41-28 Georgetown Lombardi and John Theurer to Form Cancer Research Consortium

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.